Free Trial
NASDAQ:LUNG

Pulmonx (LUNG) Stock Price, News & Analysis

Pulmonx logo
$1.69 +0.16 (+10.46%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$1.66 -0.03 (-2.07%)
As of 08/22/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Pulmonx Stock (NASDAQ:LUNG)

Key Stats

Today's Range
$1.53
$1.74
50-Day Range
$1.51
$3.78
52-Week Range
$1.47
$9.37
Volume
1.08 million shs
Average Volume
1.03 million shs
Market Capitalization
$68.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.66
Consensus Rating
Moderate Buy

Company Overview

Pulmonx Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
79th Percentile Overall Score

LUNG MarketRank™: 

Pulmonx scored higher than 79% of companies evaluated by MarketBeat, and ranked 229th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Pulmonx has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Pulmonx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Pulmonx's stock forecast and price target.
  • Earnings Growth

    Earnings for Pulmonx are expected to grow in the coming year, from ($1.55) to ($1.38) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pulmonx is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pulmonx is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Pulmonx has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Pulmonx's valuation and earnings.
  • Percentage of Shares Shorted

    3.61% of the float of Pulmonx has been sold short.
  • Short Interest Ratio / Days to Cover

    Pulmonx has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pulmonx has recently decreased by 4.86%, indicating that investor sentiment is improving.
  • Dividend Yield

    Pulmonx does not currently pay a dividend.

  • Dividend Growth

    Pulmonx does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.61% of the float of Pulmonx has been sold short.
  • Short Interest Ratio / Days to Cover

    Pulmonx has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pulmonx has recently decreased by 4.86%, indicating that investor sentiment is improving.
  • Search Interest

    11 people have searched for LUNG on MarketBeat in the last 30 days. This is an increase of 10% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Pulmonx to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Pulmonx insiders have sold 90.64% more of their company's stock than they have bought. Specifically, they have bought $71,362.00 in company stock and sold $136,044.00 in company stock.

  • Percentage Held by Insiders

    Only 6.80% of the stock of Pulmonx is held by insiders.

  • Percentage Held by Institutions

    91.04% of the stock of Pulmonx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Pulmonx's insider trading history.
Receive LUNG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulmonx and its competitors with MarketBeat's FREE daily newsletter.

LUNG Stock News Headlines

Apreo raises $130M for pivotal trial of emphysema device
Alex’s “Next Magnificent Seven” stocks
The original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Magnificent Seven—seven stocks he believes could deliver similar gains in under six years. His full breakdown is now live.tc pixel
Piper Sandler Downgrades Pulmonx (LUNG)
Pulmonx Reports Second Quarter 2025 Financial Results
See More Headlines

LUNG Stock Analysis - Frequently Asked Questions

Pulmonx's stock was trading at $6.79 at the beginning of the year. Since then, LUNG shares have decreased by 75.1% and is now trading at $1.69.

Pulmonx Corporation (NASDAQ:LUNG) released its earnings results on Wednesday, July, 30th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.02. The company had revenue of $23.86 million for the quarter, compared to analysts' expectations of $23.46 million. Pulmonx had a negative net margin of 62.88% and a negative trailing twelve-month return on equity of 69.76%.
Read the conference call transcript
.

Pulmonx (LUNG) raised $100 million in an initial public offering on Thursday, October 1st 2020. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Securities and Morgan Stanley served as the underwriters for the IPO and Stifel, Wells Fargo Securities and Canaccord Genuity were co-managers.

Top institutional investors of Pulmonx include Primecap Management Co. CA (12.67%), JPMorgan Chase & Co. (1.45%), Bank of America Corp DE (1.18%) and Connor Clark & Lunn Investment Management Ltd. (0.54%). Insiders that own company stock include Glendon E French III, Derrick Sung, Geoffrey Beran Rose, David Aaron Lehman, Mehul Joshi, Daniel P Florin, Richard Ferrari, John Mckune and Alissa Hsu Lynch.
View institutional ownership trends
.

Shares of LUNG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pulmonx investors own include JPMorgan Chase & Co. (JPM), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX), Advanced Micro Devices (AMD) and Home Depot (HD).

Company Calendar

Last Earnings
7/30/2025
Today
8/22/2025
Next Earnings (Estimated)
10/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MEDICAL INFO SYS
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:LUNG
CIK
1127537
Fax
N/A
Employees
250
Year Founded
N/A

Price Target and Rating

High Price Target
$16.00
Low Price Target
$2.50
Potential Upside/Downside
+353.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.43)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$56.39 million
Net Margins
-62.88%
Pretax Margin
-62.28%
Return on Equity
-69.76%
Return on Assets
-36.26%

Debt

Debt-to-Equity Ratio
0.54
Current Ratio
5.35
Quick Ratio
4.63

Sales & Book Value

Annual Sales
$83.79 million
Price / Sales
0.82
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.70 per share
Price / Book
0.99

Miscellaneous

Outstanding Shares
40,750,000
Free Float
37,976,000
Market Cap
$68.87 million
Optionable
Optionable
Beta
0.43

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:LUNG) was last updated on 8/23/2025 by MarketBeat.com Staff
From Our Partners